Mesothelioma | Mesothelioma news | Breaking lung cancer news | Mesothelioma

News

Advertisers:

Hana Biosciences Begins Talotrexin Phase II Clinical Trials ...

... Talotrexin is a novel nonpolyglutamatable antifolate drug which has demonstrated improved antitumor activity in a broad spectrum of preclinical cancer models by targeting dihydrofolate reductase to prevent DNA synthesis and inhibit tumor growth.

According to the company, the primary objective of this Phase II portion of an ongoing Phase I/II open-label study is to demonstrate an improvement in overall survival.

Interim results of the study suggested that Talotrexin is well tolerated over multiple cycles of therapy.

The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here.

This information is NOT a recommendation or solicitation to buy or sell any securities.

Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use.

Please click the link to view those terms.

Follow this link to read ou...